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Objectives: To examine inpatient utilization among patients with cystic fibrosis 
(CF) and homozygous for the F508del CFTR gene mutation. MethOds: Medical 
chart data from patients with CF ≥ 12 years old were collected in France, Germany, 
Italy, Spain, Australia and Canada. Demographics and clinical characteristics were 
obtained for a 12-month baseline period and a follow-up period ranging from 2-36 
months. Proportions of patients hospitalized, hospitalization rates, and length of 
stay were assessed overall and by age (12-17, ≥ 18 years), lung function (percent 
predicted forced expiratory volume in 1 second [ppFEV1] ≥ 70%, 41-69%, ≤ 40%), and 
country. Results: Data for 523 patients were included. Baseline mean ± SD age was 
24.8 ± 9.5 years and mean ± SD ppFEV1 was 67.1 ± 22.9%. Over a mean of 27 months 
follow-up, 19% of patients had 1 hospitalization, 11% had 2, and 37% had ≥ 3. The 
mean ± SD rate of hospitalizations was 1.2 ± 1.5 per patient-year. In the follow-up 
period, the proportion of patients with at least 1 hospitalization and the rate of 
hospitalization were highest for the severe ppFEV1 group relative to moderate and 
mild groups (86%, 73%, and 55% and 2.1 ± 2.0, 1.4 ± 1.6 and 0.7 ± 1.1 per patient-year 
respectively). The overall mean length of stay was 10.7 ± 7.5 days; it was 9.2 ± 6.8 days 
for the mild lung function group vs 11.0 ± 6.7 days for the severe group. The hospi-
talization rate ranged from 0.6 ± 1.1 per patient-year in Spain to 1.7 ± 1.9 in Australia; 
trends by lung function were consistent across countries. cOnclusiOns: Patients 
with CF and homozygous for the F508del CFTR gene mutation have high rates of 
hospitalization. Hospitalization rate varies by country, but is consistently higher 
for patients with the lowest lung function, congruent with a progressive disease.
SYStemIC dISorderS/CondItIonS – Patient-reported outcomes & Patient 
Preference Studies
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Objectives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, 
progressive, debilitating and life-threatening neurodegenerative disease. The pur-
pose of this study was to assess the health-related quality of life (HRQoL) impair-
ment of TTR-FAP disease versus Portuguese general population. Literature on 
TTR-FAP patients HRQoL is scarce at worldwide level and no evidence on HRQoL 
index score for Portugal has been published. MethOds: HRQoL was measured using 
the validated EuroQoL five dimensions three levels (EQ5D-3L) questionnaire being 
the index score (utility) calculated trough the Portuguese scoring algorithm. The 
Portuguese general population reference set (n = 1500) was pooled with TTR-FAP 
patients specific data (n = 1091) extracted from Transthyretin Amyloidosis Outcomes 
Survey (THAOS) registry. Demographic variables include gender and age. Ordinary 
Least Squares (OLS) regression for utility was set to test if being asymptomatic 
carrier caused HRQoL impairment, conditional in other individual characteristics. 
Generalized linear models (GLM) were specified for disutility in order to disentan-
gle and quantify TTR-FAP effect on HRQoL versus Portuguese general population. 
Akaike information criteria (AIC) were used to select the most adequate statistical 
model. Results: In a scale from -0.50 to 1.00 the average utility score was 0.76 (0.25) 
for general population, 0.823 (0.24) for TTR-FAP asymptomatic carriers (n= 525) and 
0.50(0.37) for symptomatic TTR-FAP patients (n= 566). OLS including independent 
gender and age variables, indicated no significant statistical effect on utility for 
being a TTR-FAP asymptomatic carrier (p-value 0.54) versus general population. 
GLM (AIC -0.58) detected a significant statistical effect for gender, age and being 
symptomatic TTR-FAP patient. Average women aged 44 years and symptomatic 
TTR-FAP patient, has a 40% impairment on utility versus women aged 44 years from 
general population. cOnclusiOns: The preference-based utility measures used 
in this study adequately disentangle TTR-FAP disease impact on patient’s health-
related quality of life. This study allows us to quantify the large HRQoL effect that 
TTR-FAP induces.
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Objectives: Economic evaluations of Gaucher disease type 1 (GD1) performed to 
date have used utilities for narrowly defined GD1 health states derived from spe-
cific patient populations. The aim of this study was to calculate alternative utilities 
for GD1 health states based on a standard disease severity measure. MethOds: 
Health states were based on components of the Disease Severity Scoring System 
(DS3), a validated measure capturing hematologic, visceral, and bone domains of 
GD1. Nine states were defined using combinations of DS3 severity categories (mild, 
moderate, marked, and severe) and the presence or absence of bone pain (BP) or 
skeletal complications (SSC): mild, mild+BP, mild+SSC, moderate, moderate+SSC, 
marked, marked+SSC, severe, and severe+SSC. DS3 and quality of life (SF-36) data 
came from a sample of GD1 patients enrolled in the ICGG Gaucher Registry (275 
observations, 101 patients). SF-36 data were converted to UK EQ-5D utilities using 
published methods. We fitted a generalized estimating equation, accounting for 
multiple observations per patient, containing terms for DS3 severity categories, BP, 
Objectives: The objective of this study was to assess the cost-effectiveness and 
cost-utility of dasatinib versus FLAM (fludarabine, cytarabine, mitoxantrone) chemo-
therapy in treatment of adult patients with Ph+ ALL with resistance or intolerance 
to prior therapy from the public payer’s perspective in Poland. MethOds: The 
constructed Markov model compared the costs and health effects of dasatinib and 
FLAM treatment for the average patient in the life-time horizon. The model included 
the following health states: survival without progression, survival after allogeneic 
hematopoietic stem cell transplantation (allo-HSCT), survival after progression 
and death. Data on clinical effectiveness of dasatinib and FLAM were retrieved 
from single-arm clinical trials, whereas data for overall survival after allo-HSCT 
and after progression was taken from long-term studies. The utilities for all health 
states were identified by systematic review. The following costs from public payer’s 
perspective were considered: substances and their administration (chemotherapy), 
monitoring, allo-HSCT, monitoring and chemotherapy after allo-HSCT and palliative 
care. Discount rates of 5% for costs and 3.5% for benefits were used. Results: The 
amount of life years gained associated with dasatinib arm and FLAM arm in the 
life-time horizon was 1.79 LYG and 1.17 LYG, respectively. Treatment with dasatinib 
resulted in 1.48 QALY and with FLAM – 0.94 QALY. The incremental cost-effective-
ness ratio (ICER) of dasatinib versus FLAM was estimated to be € 24,145/LYG from the 
perspective of Polish National Health Fund and it is below the threshold accepted 
for Poland (€ 27,275/QALY). The result of cost-utility analysis are almost equal to the 
threshold accepted for Poland and amount to € 28,146/QALY. cOnclusiOns: Taking 
into account the status ALL as ultra-rare disease and the results of economic evalua-
tion, dasatinib is the cost-effective strategy in comparison with FLAM chemotherapy 
in treatment Ph+ ALL patients with resistance or intolerance to prior therapy from 
the public payer’s perspective in Poland.
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Objectives: The introduction of complementary foods around the age of six month 
is necessary as infant’s need for energy and nutrients starts to exceed what is 
provided by breast milk. One of the key nutrients that infant’s demand could not 
be met only by partial breastfeeding is iron. The objective of this study is to shed 
some light on the role of complementary foods on the iron status of children using 
the food categories reported in the Indian National Family Health Survey 2005-06 
(NFHS-3). MethOds: The analysis presents the results of three set of regressions 
to associate hemoglobin / anemia levels and 17 feeding categories controlling for 
cofounders. First, ordinary least square (OLS) regressions on the hemoglobin level 
shown. Second, logistic regressions were used to estimate the odd ratio of becoming 
anemic and moderate or severe anemic. Finally, with proportional odds (ordered 
logit) model it was estimated the risk from passing to one to other category in 
anemia. Results: “Commercial fortified baby food” together with “partial breast-
feeding” and “infant formula” having the stronger positive and statistical significant 
association with iron status for infants aged six to 23 months. Additionally, “fruits 
rich in vitamin A” and “meat and fish” have also a significantly positive association 
with iron status. On the contrary, “tea or coffee”, “no commercial porridge” and 
“bread or noodles” categories tend to have a significant negative association with 
iron measurement. cOnclusiOns: Infants in India are introduced relatively late to 
iron rich foods which would allow them to replenish their iron stores from birth at 
the appropriate moment. Infant nutritional guidelines should emphasis the benefits 
of fortified baby food as well as a variety of food that would enhance the iron status 
on this highly vulnerable age group.
PSY77
retroSPeCtIve Cohort StudY uSIng data From the uk ClInICal 
PraCtICe reSearCh datalInk and hoSPItal ePISode StatIStICS to 
aSSeSS unPlanned hoSPItalISatIon In PatIentS WIth multIPle 
mYeloma
Raluy-Callado M1, Lambrelli D1, DeCosta L2, Gonzalez-McQuire S3
1Evidera, London, UK, 2Amgen Ltd., Uxbridge, UK, 3Amgen (Europe) GmbH, Zug, Switzerland
Objectives: Understanding resource use in multiple myeloma (MM) is important 
for assessing the value of new treatments. This study investigated unplanned 
hospitalisations and factors associated with increased incidence of hospitalisa-
tion in patients with MM. MethOds: Primary care data from the UK Clinical 
Practice Research Datalink and Hospital Episode Statistics were collected during 
1 January–31 December 2010 for adults who were alive and already diagnosed 
with MM on 1 January 2010. The primary outcome, unplanned hospitalisation, 
was defined as an emergency admission involving an overnight stay. Patient and 
disease characteristics were reported according to hospitalisation status and num-
ber of hospitalisations. Results: At baseline, median age of the 769 patients was 
72 years and median time since diagnosis was 3.1 years. 31.6% of patients had at 
least one unplanned hospitalisation; of these, 43.2% were rehospitalised during the 
study period. Patients with unplanned hospitalisations were older (median 74 vs 
71 years) and more likely to have renal failure (43.6% vs 31.2%) or cardiac disease 
(40.3% vs 29.1%) than those without hospitalisation (p< 0.005). There were no sig-
nificant differences in the prevalence of diabetes or prior stem cell transplantation. 
Admissions were most frequently to general medicine (35.7%) or haematology 
(19.8%) departments. Excluding MM, hospitalisations were most commonly for 
acute lower respiratory infection (6.6%) and lobar pneumonia (5.4%). Stays were 
longer for patients with at least two unplanned hospitalisations than for those 
with one (mean 12 vs 10 days; p= 0.0761). cOnclusiOns: Renal failure and cardiac 
disease (common among elderly MM patients) were significantly associated with 
unplanned hospitalisations. Admissions were often lengthy and required treat-
ment in specialist units (e.g. haematology departments). Such hospitalisations 
are likely to incur high costs. The results indicate an unmet need in MM manage-
ment to more successfully control the burden of the disease and thereby reduce 
associated resource utilisation.
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annual questionnaire that was specifically designed to assess the symptoms and 
problems of the disease. Results: We review our results of over 10 years of follow-
up, and discuss the survey’s contribution to the field. Tracking 408 Pompe patients 
between 2002 and 2013, the cumulative data reveals the broad range of clinical man-
ifestations that interfere with patients’ lives. The survey allowed us to quantify the 
rate of disease progression and the positive effects of ERT on patients’ quality of life, 
fatigue, and participation in daily life. Furthermore, it showed for the first time that 
survival is reduced in adult Pompe disease and improved by ERT. cOnclusiOns: 
Our results show that a patient survey can serve as a valuable and reliable tool for 
obtaining quantifiable information on the natural course of a rare disease and on 
the effects of therapy in a large cohort over a very long time. Most importantly, by 
working with patient reported outcomes, the survey provides the data that is truly 
relevant to the patient and complementary to clinical datasets.
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Objectives: To conduct a systematic review of the literature and assess the impact 
of orthopaedic surgery on the health-related quality of life (HRQoL) of haemophilia 
patients with or without inhibitors. MethOds: Searches were conducted in the 
MEDLINE, EMBASE, EconLit, Cochrane library and the Center for Reviews and 
Dissemination databases from 2000 onwards. A broad search including both Medical 
Subject Heading (MeSH) terms and key words related to haemophilia and HRQoL 
was conducted. We included only the publications reporting pre- and post-surgery 
HRQoL data and all orthopedic interventions were considered. Congress abstracts 
from 2010 were also reviewed. Abstracts and full text articles were screened by 
two reviewers and conflicts arbitrated. Results: A total of 1,471 articles were 
retrieved. Following the screening process, 8 full-text articles reporting pre- and 
post-surgery HRQoL data for patients who received ankle arthrodesis, total knee 
replacement, ankle replacement or hip arthroplasty were included. Seven studies 
used patient-reported measures and only one study estimated the EQ-5D using 
indirect matching techniques. Of the seven studies, four used the visual analogue 
scale (VAS). Three concluded that post-operative pain was significantly lower and 
only one study reported that although pain decreased post-surgery, moderate pain 
remained among patients who underwent multiple joint procedures and received 
ankle arthrodesis. Of the four studies that reported SF-36/SF-12 scores, significant 
gains in physical health scores were observed in three and higher mental health 
scores were reported in one study. Disease-specific measures, Western Ontario and 
McMaster University (WOMAC) and Oxford Knee Score, were assessed by two studies 
and improvements in pain and physical functioning were observed on both scales. 
Evidence from SF-12 summary scores suggests that the improvements in physical 
functioning are similar for patients with and without inhibitors. cOnclusiOns: 
Orthopaedic surgery improves the HRQoL of haemophilia patients with severe 
arthropathy.
PSY85
health StateS WorSe than dead In an elderlY PoPulatIon – 
PrevalenCe and the SIgnIFICanCe oF ChronIC PaIn
Bernfort L, Gerdle B, Levin L
Linköping University, Linköping, Sweden
Objectives: When applying accepted health economic methods, it is not uncom-
mon to find valuations of patients’ health states that are worse than dead. 
Hypothetical valuations (the UK value set) of states according to the EQ-5D resulted 
in 82 of 243 possible states being valued as worse than dead. The presence of health 
states valued worse than dead risks giving rise to counter-intuitive consequences 
when incorporated in health economic analyses. The purpose of this study was 
therefor to investigate the presence of such states in an exposed population, namely 
people 65 years and older. MethOds: Based on a Swedish epidemiological popu-
lation survey study directed to 10 000 persons 65 years and older the occurrence 
of states worse than dead were investigated and related to prevalence and inten-
sity of chronic pain. Results: Health states worse than dead were found in 1.8 % 
of the 6618 responders to the questionnaire. Among persons with severe chronic 
pain the prevalence was 16.7 % and among persons with moderate and no or mild 
chronic pain the prevalence of states worse than dead were 2.7 % and 0.8 % respec-
tively. Prevalence of these states clearly increased with age and female gender. Of 
women 85 years and older with severe chronic pain 38.7 % were in states worse 
than dead. cOnclusiOns: Health states worse than dead are not rare in an elderly 
population and covariate with chronic pain, age and female gender. The prevalence 
of states worse than dead are highly dependent on the value set applied, and will 
have consequences for assessments of treatments for elderly with chronic pain. 
Based on the results of this study it should be investigated whether and to what 
extent health states worse than dead exist when using experience based valuation 
methods, which is the preferred approach in some settings/countries.
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and SSC. Average utilities for each health state were predicted from the regression 
coefficients. Utilities were also estimated using individual health state dummy 
variables in a sensitivity analysis. Results: Utilities for health states without BP 
or SSC were 0.76 for mild, 0.69 for moderate, 0.64 for marked, and 0.60 for severe. 
The utilities for states with bone symptoms were lower: 0.67 for mild+BP, 0. 68 
for mild+SSC, 0.61 for moderate+SSC, 0.56 for marked+SSC, and 0.52 severe+SSC. 
Sensitivity analysis utilities were similar but less precise and sometimes less clini-
cally plausible. cOnclusiOns: Compared with the norm for the EQ-5D utility index 
in the UK (0.86), these utility estimates reflect the substantial quality of life impact 
of GD1, especially with skeletal complications. These utilities can be used in future 
economic evaluations of GD1 therapies to calculate quality-adjusted life years.
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Objectives: In the past few years, a number of biological drugs to treat pemphigus 
have successfully passed through phase 2 and 3; however, none of the clinical trials 
in pemphigus has used preference-based outcome measures to generate utilities 
for economic evaluations, so far. In attempt to fill this gap, the objective of this 
study is to measure utility weights for hypothetical pemphigus vulgaris (PV) and 
foliaceus (PF) health states in a general population sample. MethOds: Three health 
state profiles were developed: an uncontrolled PV, an uncontrolled PF and a treated 
pemphigus state. Health state vignettes combined a description of living with pem-
phigus including skin and mucosal symptoms, possible food avoidance, bathing/
clothing issues, and effects on work and social life. Utilities were obtained from 
a convenience sample of 106 adults using visual analogue scale (VAS, 0-10 scale) 
and time trade-off (TTO). Lead-time TTO was applied for health states considered 
worse than dead. Utilities in this study were ranging between -1 (lower anchor of 
worse than dead) and 1 (perfect health) Results: Mean VAS scores for PV, PF and 
treated pemphigus were 2.46±1.54, 3.77±1.69 and 6.35±1.60, respectively. The esti-
mated utility weights attached for the health states were as follows: PV 0.34±0.38, 
PF 0.51±0.31 and treated pemphigus 0.73±0.31. Overall 13% and 5% judged PV and 
PF as being worse than dead. For both VAS and TTO values, significant difference 
revealed between each of the three health states (p< 0.001). cOnclusiOns: This 
study provides the first utility weights in pemphigus. Disutility associated with 
uncontrolled pemphigus was found worse than in uncontrolled psoriasis or atopic 
dermatitis. Successful treatment of pemphigus may yield significant utility gain 
(0.22-0.39). Utilities elicited in this study may be used in cost-effectiveness analysis 
of new pemphigus treatments.
PSY82
“FIrSt and ForemoSt Battle the vIruS” - PatIent PreFerenCeS In 
antIvIral theraPY For hePatItIS C
Mühlbacher AC, Bethge S, Sadler A
Hochschule Neubrandenburg, Neubrandenburg, Germany
Objectives: Treatment options for patients with hepatitis C have made tremen-
dous progress in the last 5 years. Innovative antiviral-therapies promise a huge 
reduction of burden of disease and side-effects accompanied by an increase of 
patient’s benefit. It is unclear, however, what properties generate the highest benefit 
for patients. MethOds: A systematic literature search was conducted to identify 
patient-relevant outcomes . Within N= 14 semi-structured interviews the decision 
model was generated. Eight patient relevant characteristics were identified and 
described by three or six levels. For the discrete choice experiment, an experimen-
tal design (3*3+5*6) was generated using Ngene-Software. The design consisted 72 
choices, which were divided into 6 blocks. The survey was conducted in august 2014 
with computer-assisted personal interviews. Results: N= 561 hepatitis C-patients 
(58,1% male) within different treatment states participated. The preference analysis 
(random parameter logit estimation (with 95%CI)) showed a predominance for the 
attribute “sustained virological response 6 month after end of treatment”(coef.:1,108). 
A split second rank is occupied by the possible side effects “anemia”(coef.:0.396) and 
“rash”(coef.:0.372). The attributes that describe the administration of the treatment 
“number of interferon injections” (coef.:0.224) and “duration of treatment”(coef.:0.183) 
share the third place. The attributes “fatigue/exhaustion”(coef.:0.088) and “nausea/
diarrhea”(coef.:0.067) follow. Within the treatment decision of hepatitis C-patients 
the attribute “headache”(coef.:0.036) was not taken into account, as reflected by the 
lack of significance. cOnclusiOns: In this study, the essential decision criteria 
for an optimal antiviral therapy of hepatitis C from the Hep C patients’ view were 
obtained by using a DCE. Thereby SVR is ranked highest against all patient relevant 
side effects and mode of administration characteristics. In the context of this study 
it could be demonstrated that with the help of the DCE patient-relevant properties 
can be weighted in terms of possible treatment options. The DCE stands out by a high 
degree of realism and good handling for the patient.
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Objectives: Pompe disease is a rare, progressive lysosomal storage disorder for 
which enzyme therapy (ERT) became available in 2006. Four years earlier, the IPA/
Erasmus MC survey, an international longitudinal prospective survey, was estab-
lished to collect information on the natural course of the disease and its burden on 
patients. MethOds: The survey is a collaboration between Erasmus MC University 
Medical Center and the International Pompe Association (IPA) and comprises an 
